Scandium-47 (47Sc)

Scandium-47 (47Sc) is a versatile theranostic radioisotope increasingly recognized for its potential in targeted radionuclide therapy and diagnostic imaging. It is not a biological target itself but serves as a radioactive payload that must be conjugated to a targeting ligand, such as a peptide or antibody, to reach specific tissues (International Atomic Energy Agency, 2021). 47Sc emits medium-energy beta-minus particles suitable for treating small-to-medium-sized tumors and a gamma photon ideal for SPECT imaging, making it a true theranostic agent. Its chemical properties are similar to other trivalent radiometals like Lutetium-177 and Yttrium-90, allowing it to be incorporated into existing chelator frameworks like DOTA (Müller et al., 2014, Journal of Nuclear Medicine). The isotope's 3.35-day half-life provides a favorable window for both therapeutic delivery and imaging, particularly when paired with targeting vectors that have intermediate circulation times. Furthermore, it can be used in a matched-pair approach with positron-emitting scandium isotopes (43Sc or 44Sc) for high-resolution PET imaging, facilitating precise patient selection and treatment planning.

Other names

Sc-4747-ScandiumRadioactive scandiumScandium radionuclide

Scandium-47 functions as a theranostic radionuclide that delivers targeted ionizing radiation to malignant cells. Upon localization to a specific site via a targeting vector (such as a peptide or antibody), it undergoes beta-minus decay, emitting electrons with an average energy of 162 keV that cause lethal DNA damage, including single and double-strand breaks, in nearby cells (Müller et al., 2014, Journal of Nuclear Medicine). Simultaneously, its 159 keV gamma emission allows for real-time biodistribution monitoring and dosimetry via Single Photon Emission Computed Tomography (SPECT) imaging (Domnanich et al., 2017, EJNMMI Radiopharmacy and Chemistry).